Loar Holdings Inc. Reports Q3 2024 Results, Upward Revision to 2024 and Initial 2025 Guidance
WHITE PLAINS, NY / ACCESSWIRE / November 13, 2024 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the third quarter of 2024.
Third Quarter 2024
Net sales of $103.5 million, up 25.0% compared to the prior year's quarter.
Net income for Q3 2024 was $8.7 million, up $5.8 million compared to the prior year's quarter.
Diluted earnings per share of $0.09.
Adjusted EBITDA of $38.1 million, up 31.8% compared to the prior year's quarter.
Net income margin for the quarter improved to 8.4% from the prior year's quarter of 3.4%.
Adjusted EBITDA Margin for the quarter was 36.8% compared to 34.9% for the prior year's quarter.
Adjusted Earnings Per Share of $0.15.
"Our third quarter results showcased our continued execution across all four of our strategic value drivers," stated Dirkson Charles, Loar CEO and Executive Co-Chairman of the Board of Directors. "We again achieved record net sales and Adjusted EBITDA, driven by strong demand in both our commercial and defense end-markets."
Loar reported net sales for the quarter of $103.5 million, an increase of $20.7 million or 25.0% over the prior year's quarter. Organically(1), net sales increased 16.5% or $13.7 million, to $96.5 million.
Net income for the quarter increased $5.8 million to $8.7 million from a net income of $2.9 million for the comparable quarter a year ago. The increase in net income for the quarter was primarily driven by an increase in operating income and a decrease in interest expense.
Adjusted EBITDA for the quarter was $38.1 million, an increase of 31.8% or $9.2 million compared to the prior year's quarter. Adjusted EBITDA as a percentage of net sales was 36.8%, compared to 34.9% in the third quarter of the prior year. The increase in Adjusted EBITDA as a percentage of net sales is primarily attributed to the execution of our strategic value drivers and operating leverage from higher sales levels.
Year-to-Date
Net sales for the first nine months ended September 30, 2024, were $292.4 million, an increase of $61.3 million or 26.5% over the comparable period of the prior year. Organically(1), net sales increased 14.9% or $34.5 million, to $265.6 million.
Net income year-to-date increased $22.6 million to $18.5 million from a net loss of $4.0 million for the comparable period a year ago.
Adjusted EBITDA for the nine months of 2024 was $106.2 million, an increase of 27.1% or $22.7 million over the comparable period a year ago. Adjusted EBITDA as a percentage of net sales was 36.3%, compared to 36.1% for the first nine months of the prior year.
Please see the attached Table 4 for a reconciliation of net income (loss) to EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin for the periods discussed in this press release.
(1) | Net organic sales represent net sales from our existing businesses for comparable periods and exclude net sales from acquisitions. We include net sales from new acquisitions in net organic sales from the 13th month after the acquisition on a comparative basis with the prior period. |
Full Year 2024 Outlook - Revised Upward
"As a result of the successful closure of the acquisition of Applied Avionics and our strong business performance, we are revising our full year 2024 guidance," stated Glenn D'Alessandro, Loar Chief Financial Officer and Treasurer. "This guidance therefore reflects higher interest and amortization costs as a result of the acquisition of Applied Avionics."
Net sales - between $390 and $394 million, up from $374 million to $378 million
Net income - between $19.0 and $20.0 million, down from $28.4 million to $29.6 million
Adjusted EBITDA - between $141 and $143 million, up from $134 million to $136 million
Diluted earnings per share - between $0.20 to $0.22
Net income margin - approximately 5%, down from approximately 8%
Adjusted Earnings Per Share -between $0.35 and $0.37, down from $0.44 to $0.46
Adjusted EBITDA Margin - remains at approximately 36%
Interest expense - approximately $54 million, up from $42 million
Market Assumptions - Full year outlook is based on the following assumptions:
Commercial, Business Jet, and General Aviation OEM growth of high double-digits, up from mid double-digits
Commercial, Business Jet, and General Aviation aftermarket growth of mid double-digits
Defense growth of high double-digits, up from mid double-digits
Full Year 2025 Outlook
"As we near the end of the year, the strength of our backlog gives us the visibility needed to look ahead to 2025. We believe our 2025 guidance outlines the strong demand we see across all the end-markets in which we participate," stated Mr. Charles.
Net sales - between $470 million and $480 million
Net income - between $33.0 million and $37.0 million
Adjusted EBITDA - between $176 million and $180 million
Diluted earnings per share - between $0.35 and $0.40
Net income margin - approximately 7%
Adjusted Earnings Per Share -between $0.45 and $0.50
Adjusted EBITDA Margin - approximately 37.5%
Interest expense - approximately $60 million
Market Assumptions - Full year outlook is based on the following assumptions:
Commercial, Business Jet, and General Aviation OEM growth of high single-digits
Commercial, Business Jet, and General Aviation aftermarket growth of high single-digits
Defense growth of high double-digits
Adjusted EBITDA, Adjusted Earnings Per Share and Adjusted EBITDA Margin are non-GAAP financial measures provided in these "Full Year 2024 Outlook - Revised Upward" and the "Full Year 2025 Outlook" sections on a forward-looking basis. The Company does not provide a reconciliation of such forward-looking measures to the most directly comparable financial measures calculated and presented in accordance with GAAP because to do so would be potentially misleading and not practical given the difficulty of projecting event-driven transactional and other non-core operating items in any future period. The magnitude of these items, however, may be significant.
Earnings Conference Call
A conference call for investors and security analysts is scheduled on Wednesday November 13, 2024, at 10:30 a.m., Eastern Time. To participate in the call telephonically please dial +1 877-407-0670 / +1 215-268-9902. International participants can find a list of toll-free numbers here. A live audio webcast will also be available at the following link as well as through the Investor section of Loar Holdings website; https://ir.loargroup.com
The webcast will be archived and available for replay later in the day.
About Loar Holdings Inc.
Loar Holdings Inc. is a diversified manufacturer and supplier of niche aerospace and defense components that are essential for today's aircraft and aerospace and defense systems. Loar has established relationships across leading aerospace and defense original equipment manufacturers and Tier Ones worldwide.
Non-GAAP Supplemental Information
We present in this press release certain financial information based on our EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Earnings Per Share. References to "EBITDA" mean earnings before interest, taxes, depreciation and amortization, references to "Adjusted EBITDA" mean EBITDA plus, as applicable for each relevant period, certain adjustments as set forth in the reconciliations of net income (loss) to EBITDA and Adjusted EBITDA, and references to "Adjusted EBITDA Margin" refer to Adjusted EBITDA divided by net sales. References to Adjusted Earnings Per Share mean net income plus certain adjustments as set forth in the reconciliations below to derive Adjusted EBITDA from EBITDA, less the tax effect of these adjustments. EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Earnings Per Share are not measurements of financial performance under U.S. GAAP. We present EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin because we believe they are useful indicators for evaluating operating performance. In addition, our management uses Adjusted EBITDA to review and assess the performance of the management team in connection with employee incentive programs and to prepare its annual budget and financial projections. Moreover, our management uses Adjusted EBITDA of target companies to evaluate acquisitions.
Although we use EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin as measures to assess the performance of our business and for the other purposes set forth above, the use of non-GAAP financial measures as analytical tools has limitations, and you should not consider any of them in isolation, or as a substitute for analysis of our results of operations as reported in accordance with U.S. GAAP. Some of these limitations are:
EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin do not reflect the significant interest expense, or the cash requirements necessary to service interest payments on our indebtedness.
Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and the cash requirements for such replacements are not reflected in EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin.
EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin exclude the cash expense we have incurred to integrate acquired businesses into our operations, which is a necessary element of certain of our acquisitions.
The omission of the substantial amortization expense associated with our intangible assets further limits the usefulness of EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin; and
EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin do not include the payment of taxes, which is a necessary element of our operations.
Because of these limitations, EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin should not be considered as measures of cash available to us to invest in the growth of our business. Management compensates for these limitations by not viewing EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin in isolation and specifically by using other U.S. GAAP measures, such as net sales and operating profit, to measure our operating performance. EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin are not measurements of financial performance under U.S. GAAP, and they should not be considered as alternatives to net income (loss) or cash flow from operations determined in accordance with U.S. GAAP. Our calculations of EBITDA, Adjusted EBITDA, and Adjusted EBITDA Margin may not be comparable to the calculations of similarly titled measures reported by other companies.
Future Looking Statements
This press release includes express or implied forward-looking statements. Forward-looking statements include all statements that are not historical facts including those that reflect our current views with respect to, among other things, our operations and financial performance. The words "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "future," "will," "seek," "foreseeable," the negative version of these words or similar terms and phrases may identify forward-looking statements in this press release, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release, including, but not limited to, the statements under the headings "Full Year 2024 Outlook - Revised Upward" and "Full Year 2025 Outlook," are based on management's current expectations and are not guarantees of future performance. Our expectations and beliefs are expressed in management's good faith, and we believe there is a reasonable basis for them, however, the forward-looking statements are subject to various known and unknown risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following: the almost exclusive focus of our business on the aerospace and defense industry; our heavy reliance on certain customers for a significant portion of our sales; the fact that we have in the past consummated acquisitions and our intention to continue to pursue acquisitions, and that our business may be adversely affected if we cannot consummate acquisitions on satisfactory terms, or if we cannot effectively integrate acquired operations; and the other risks and uncertainties described under "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission ("SEC") on August 13, 2024, as well as the Company's Quarterly Report on Form 10-Q that will be filed following this earnings release, and other periodic reports filed by the Company from time to time with the SEC.
These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in the forward-looking statements. Any forward-looking statement made by us in this press release speaks only as of the date of this press release and is expressly qualified in its entirety by the cautionary statements included in this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable law.
Contact
Ian McKillop
Loar Group Investor Relations
IR@loargroup.com
Loar Holdings Inc.
Table 1: - Condensed Consolidated Balance Sheets
(Unaudited, amounts in thousands except share amounts)
| September 30, 2024 |
|
| December 31, 2023 |
| |||
Assets |
|
|
|
|
|
| ||
Current assets: |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ | 55,179 |
|
| $ | 21,489 |
|
Accounts receivable, net |
|
| 66,329 |
|
|
| 59,002 |
|
Inventories |
|
| 97,887 |
|
|
| 77,962 |
|
Other current assets |
|
| 12,152 |
|
|
| 11,830 |
|
Income taxes receivable |
|
| 408 |
|
|
| 393 |
|
Total current assets |
|
| 231,955 |
|
|
| 170,676 |
|
Property, plant and equipment |
|
| 76,955 |
|
|
| 72,174 |
|
Finance lease assets |
|
| 2,240 |
|
|
| 2,448 |
|
Operating lease assets |
|
| 5,916 |
|
|
| 6,297 |
|
Other long-term assets |
|
| 16,200 |
|
|
| 11,420 |
|
Intangible assets, net |
|
| 447,123 |
|
|
| 316,542 |
|
Goodwill |
|
| 691,658 |
|
|
| 470,888 |
|
Total assets |
| $ | 1,472,047 |
|
| $ | 1,050,445 |
|
|
|
|
|
|
|
|
| |
Liabilities and equity |
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
| $ | 16,224 |
|
| $ | 12,876 |
|
Current portion of long-term debt |
|
| 6,028 |
|
|
| 6,896 |
|
Current portion of finance lease liabilities |
|
| 221 |
|
|
| 190 |
|
Current portion of operating lease liabilities |
|
| 612 |
|
|
| 609 |
|
Income taxes payable |
|
| 6,265 |
|
|
| 6,133 |
|
Accrued expenses and other current liabilities |
|
| 29,334 |
|
|
| 24,776 |
|
Total current liabilities |
|
| 58,684 |
|
|
| 51,480 |
|
Deferred income taxes |
|
| 36,820 |
|
|
| 36,785 |
|
Long-term debt, net |
|
| 596,074 |
|
|
| 528,582 |
|
Finance lease liabilities |
|
| 3,234 |
|
|
| 3,401 |
|
Operating lease liabilities |
|
| 5,464 |
|
|
| 5,802 |
|
Environmental liabilities |
|
| - |
|
|
| 1,145 |
|
Other long-term liabilities |
|
| 1,957 |
|
|
| 5,109 |
|
Total liabilities |
|
| 702,233 |
|
|
| 632,304 |
|
|
|
|
|
|
|
|
| |
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Equity: |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 1,000,000 shares authorized, and no shares issued or outstanding |
|
| - |
|
|
| - |
|
Common stock, $0.01 par value, 485,000,000 shares authorized; 89,703,571 issued and outstanding at September 30, 2024 |
|
| 897 |
|
|
| - |
|
Additional paid-in capital |
|
| 793,167 |
|
|
| - |
|
Accumulated deficit |
|
| (24,245) |
|
|
| - |
|
Accumulated other comprehensive loss |
|
| (5) |
|
|
| - |
|
Member's equity |
|
| - |
|
|
| 418,141 |
|
Total equity |
|
| 769,814 |
|
|
| 418,141 |
|
Total liabilities and equity |
| $ | 1,472,047 |
|
| $ | 1,050,445 |
|
Loar Holdings Inc.
Table 2: Condensed Consolidated Statements of Operations
(Unaudited, amounts in thousands except per common share and per common unit amounts)
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| ||||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| ||||||
Net sales |
| $ | 103,519 |
|
| $ | 82,807 |
|
| $ | 292,378 |
|
|
| $ | 231,042 |
|
Cost of sales |
|
| 50,615 |
|
|
| 42,176 |
|
|
| 147,515 |
|
|
|
| 116,904 |
|
Gross profit |
|
| 52,904 |
|
|
| 40,631 |
|
|
| 144,863 |
|
|
|
| 114,138 |
|
Selling, general and administrative expenses |
|
| 30,186 |
|
|
| 21,863 |
|
|
| 80,362 |
|
|
|
| 60,210 |
|
Transaction expenses |
|
| 1,444 |
|
|
| 2,022 |
|
|
| 2,549 |
|
|
|
| 2,626 |
|
Other income, net |
|
| 1,574 |
|
|
| 356 |
|
|
| 4,441 |
|
|
|
| 483 |
|
Operating income |
|
| 22,848 |
|
|
| 17,102 |
|
|
| 66,393 |
|
|
|
| 51,785 |
|
Interest expense, net |
|
| 9,962 |
|
|
| 17,155 |
|
|
| 38,332 |
|
|
|
| 49,125 |
|
Refinancing costs |
|
| - |
|
|
| - |
|
|
| 1,645 |
|
|
|
| - |
|
Income (loss) before income taxes |
|
| 12,886 |
|
|
| (53 | ) |
|
| 26,416 |
|
|
|
| 2,660 |
|
Income tax (provision) benefit |
|
| (4,230 | ) |
|
| 2,907 |
|
|
| (7,870 | ) |
|
|
| (6,702 | ) |
Net income (loss) |
| $ | 8,656 |
|
| $ | 2,854 |
|
| $ | 18,546 |
|
|
| $ | (4,042 | ) |
Net income per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
Basic |
| $ | 0.10 |
|
| n/a |
|
| $ | 0.21 |
|
| n/a |
| |||
Diluted |
| $ | 0.09 |
|
| n/a |
|
| $ | 0.20 |
|
| n/a |
| |||
Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
Basic |
|
| 89,704 |
|
| n/a |
|
|
| 88,722 |
|
| n/a |
| |||
Diluted |
|
| 91,931 |
|
| n/a |
|
|
| 90,755 |
|
| n/a |
| |||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
Net income (loss) per common unit |
|
| n/a |
|
| $ | 14,000.14 |
|
|
| n/a |
|
|
| $ | (19,799.55 | ) |
Weighted average common units outstanding - basic and diluted |
|
| n/a |
|
|
| 204 |
|
|
| n/a |
|
|
|
| 204 |
|
Loar Holdings Inc.
Table 3: - Condensed Consolidated Statements of Cash Flows
(Unaudited, amounts in thousands)
| Nine Months Ended September 30, |
| ||||||
| 2024 |
|
| 2023 |
| |||
Operating Activities |
|
|
|
|
|
| ||
Net income (loss) |
| $ | 18,546 |
|
| $ | (4,042 | ) |
Adjustments to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|
|
|
Depreciation |
|
| 8,183 |
|
|
| 7,297 |
|
Amortization of intangibles and other long-term assets |
|
| 22,249 |
|
|
| 20,869 |
|
Amortization of debt issuance costs |
|
| 931 |
|
|
| 2,132 |
|
Amortization of inventory step-up |
|
| 276 |
|
|
| 201 |
|
Stock-based compensation |
|
| 7,568 |
|
|
| 278 |
|
Deferred income taxes |
|
| (141 | ) |
|
| 622 |
|
Non-cash lease expense |
|
| 438 |
|
|
| 668 |
|
Refinancing costs |
|
| 1,645 |
|
|
| - |
|
Other income, net |
|
| (2,856 | ) |
|
| - |
|
Changes in assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
| (4,331 | ) |
|
| (11,462 | ) |
Inventories |
|
| (13,694 | ) |
|
| (12,643 | ) |
Other assets |
|
| (4,455 | ) |
|
| (3,565 | ) |
Accounts payable |
|
| 2,825 |
|
|
| 3,531 |
|
Other liabilities |
|
| (1,404 | ) |
|
| (2,384 | ) |
Environmental liabilities |
|
| (1,145 | ) |
|
| (46 | ) |
Operating lease liabilities |
|
| (392 | ) |
|
| (656 | ) |
Net cash provided by operating activities |
|
| 34,243 |
|
|
| 800 |
|
|
|
|
|
|
|
|
| |
Investing Activities |
|
|
|
|
|
|
|
|
Capital expenditures |
|
| (6,084 | ) |
|
| (7,824 | ) |
Payment for acquisitions, net of cash acquired |
|
| (383,222 | ) |
|
| (60,289 | ) |
Net cash used in investing activities |
|
| (389,306 | ) |
|
| (68,113 | ) |
|
|
|
|
|
|
|
| |
Financing Activities |
|
|
|
|
|
|
|
|
Net proceeds from issuance of common stock |
|
| 325,408 |
|
|
| - |
|
Payments of long-term debt |
|
| (287,881 | ) |
|
| (4,333 | ) |
Proceeds from issuance of long-term debt |
|
| 360,000 |
|
|
| 53,000 |
|
Financing costs and other, net |
|
| (8,876 | ) |
|
| (1,060 | ) |
Payments of finance lease liabilities |
|
| (137 | ) |
|
| (95 | ) |
Net cash provided by financing activities |
|
| 388,514 |
|
|
| 47,512 |
|
|
|
|
|
|
|
|
| |
Effect of translation adjustments on cash and cash equivalents |
|
| 239 |
|
|
| (137 | ) |
Net increase (decrease) in cash and cash equivalents |
|
| 33,690 |
|
|
| (19,938 | ) |
|
|
|
|
|
|
|
| |
Cash and cash equivalents, beginning of period |
|
| 21,489 |
|
|
| 35,497 |
|
Cash and cash equivalents, end of period |
| $ | 55,179 |
|
| $ | 15,559 |
|
|
|
|
|
|
|
|
| |
Supplemental information |
|
|
|
|
|
|
|
|
Interest paid during the period, net of capitalized amounts |
| $ | 37,495 |
|
| $ | 47,246 |
|
Income taxes paid during the period, net |
| $ | 7,925 |
|
| $ | 4,942 |
|
Loar Holdings Inc.
Table 4: Reconciliation of Net income (Loss) to EBITDA and Adjusted EBITDA
(Unaudited, amounts in thousands)
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| |||||||||||||
| 2024 |
|
| 2023 |
|
| 2024 |
|
| 2023 |
| |||||||
Net income (loss) |
|
| $ | 8,656 |
|
| $ | 2,854 |
|
|
| $ | 18,546 |
|
| $ | (4,042 | ) |
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Interest expense, net |
|
|
| 9,962 |
|
|
| 17,155 |
|
|
|
| 38,332 |
|
|
| 49,125 |
|
Refinancing costs |
|
|
| - |
|
|
| - |
|
|
|
| 1,645 |
|
|
| - |
|
Income tax provision (benefit) |
|
|
| 4,230 |
|
|
| (2,907 | ) |
|
|
| 7,870 |
|
|
| 6,702 |
|
Operating income |
|
|
| 22,848 |
|
|
| 17,102 |
|
|
|
| 66,393 |
|
|
| 51,785 |
|
Depreciation |
|
|
| 2,775 |
|
|
| 2,314 |
|
|
|
| 8,183 |
|
|
| 7,297 |
|
Amortization |
|
|
| 7,945 |
|
|
| 7,101 |
|
|
|
| 22,249 |
|
|
| 20,869 |
|
EBITDA |
|
|
| 33,568 |
|
|
| 26,517 |
|
|
|
| 96,825 |
|
|
| 79,951 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
Recognition of inventory step-ups (1) |
| 276 |
|
|
| 201 |
|
| 276 |
|
|
| 201 |
| ||||
Other income, net (2) |
|
|
| (1,574 | ) |
|
| (356 | ) |
|
|
| (4,441 | ) |
|
| (483 | ) |
Transaction expenses (3) |
|
|
| 1,444 |
|
|
| 2,023 |
|
|
|
| 2,549 |
|
|
| 2,627 |
|
Stock-based compensation (4) |
|
|
| 3,094 |
|
|
| 92 |
|
|
|
| 7,568 |
|
|
| 278 |
|
Acquisition and facility integration costs (5) |
|
|
| 1,288 |
|
|
| 432 |
|
|
|
| 3,381 |
|
|
| 917 |
|
Adjusted EBITDA |
|
| $ | 38,096 |
|
| $ | 28,909 |
|
|
| $ | 106,158 |
|
| $ | 83,491 |
|
Net sales |
|
| $ | 103,519 |
|
| $ | 82,807 |
|
|
| $ | 292,378 |
|
| $ | 231,042 |
|
Net income (loss) margin |
|
|
| 8.4 | % |
|
| 3.4 | % |
|
|
| 6.3 | % |
|
| (1.7 | )% |
Adjusted EBITDA Margin |
|
|
| 36.8 | % |
|
| 34.9 | % |
|
|
| 36.3 | % |
|
| 36.1 | % |
Represents accounting adjustments to inventory associated with acquisitions of businesses that were charged to cost of sales when inventory was sold.
Represents the reduction in the estimated contingent purchase price for the CAV Group Limited acquisition in 2024 and a grant from the U.S. Department of Transportation under the Aviation Manufacturing Jobs Protection Program in 2023.
Represents third party transaction-related costs for acquisitions comprising deal fees, legal, financial and tax due diligence expenses, and valuation costs that are required to be expensed as incurred.
Represents the non-cash compensation expense recognized by the Company for equity awards.
Represents costs incurred to integrate acquired businesses and product lines into our operations, facility relocation costs and other acquisition-related costs.
Loar Holdings Inc.
Table 5: Sales by End-Market
(Unaudited, amounts in thousands)
| Three Months Ended September 30, |
| ||||||||||||||||||||||
| 2024 |
|
| 2023 |
| |||||||||||||||||||
| OEM |
|
| Aftermarket |
|
| Total |
|
| OEM |
|
| Aftermarket |
|
| Total |
| |||||||
Commercial Aerospace |
| $ | 15,824 |
|
| $ | 29,058 |
|
| $ | 44,882 |
|
| $ | 14,574 |
|
| $ | 23,886 |
|
| $ | 38,460 |
|
Business Jet and General Aviation |
|
| 19,911 |
|
|
| 10,121 |
|
|
| 30,032 |
|
|
| 11,701 |
|
|
| 7,729 |
|
|
| 19,430 |
|
Total Commercial |
|
| 35,735 |
|
|
| 39,179 |
|
|
| 74,914 |
|
|
| 26,275 |
|
|
| 31,615 |
|
|
| 57,890 |
|
Defense |
|
| 10,152 |
|
|
| 11,810 |
|
|
| 21,962 |
|
|
| 8,004 |
|
|
| 7,218 |
|
|
| 15,222 |
|
Other |
|
| 2,976 |
|
|
| 3,667 |
|
|
| 6,643 |
|
|
| 5,667 |
|
|
| 4,028 |
|
|
| 9,695 |
|
Total |
| $ | 48,863 |
|
| $ | 54,656 |
|
| $ | 103,519 |
|
| $ | 39,946 |
|
| $ | 42,861 |
|
| $ | 82,807 |
|
| Nine Months Ended September 30, |
| ||||||||||||||||||||||
| 2024 |
|
| 2023 |
| |||||||||||||||||||
| OEM |
|
| Aftermarket |
|
| Total |
|
| OEM |
|
| Aftermarket |
|
| Total |
| |||||||
Commercial Aerospace |
| $ | 46,316 |
|
| $ | 81,101 |
|
| $ | 127,417 |
|
| $ | 40,487 |
|
| $ | 67,016 |
|
| $ | 107,503 |
|
Business Jet and General Aviation |
|
| 53,556 |
|
|
| 29,253 |
|
|
| 82,809 |
|
|
| 31,391 |
|
|
| 20,516 |
|
|
| 51,907 |
|
Total Commercial |
|
| 99,872 |
|
|
| 110,354 |
|
|
| 210,226 |
|
|
| 71,878 |
|
|
| 87,532 |
|
|
| 159,410 |
|
Defense |
|
| 26,793 |
|
|
| 32,681 |
|
|
| 59,474 |
|
|
| 22,546 |
|
|
| 21,056 |
|
|
| 43,602 |
|
Other |
|
| 10,727 |
|
|
| 11,951 |
|
|
| 22,678 |
|
|
| 15,323 |
|
|
| 12,707 |
|
|
| 28,030 |
|
Total |
| $ | 137,392 |
|
| $ | 154,986 |
|
| $ | 292,378 |
|
| $ | 109,747 |
|
| $ | 121,295 |
|
| $ | 231,042 |
|
Loar Holdings Inc.
Table 6: Reconciliation of Earnings Per Share to Adjusted Earnings Per Share
(Unaudited, amounts in thousands except per share amounts)
| Three Months Ended September 30, |
|
| Nine Months Ended September 30, |
| |||
| 2024 |
|
| 2024 |
| |||
Reported earnings per share |
|
|
|
|
|
| ||
Net income |
| $ | 8,656 |
|
| $ | 18,546 |
|
Denominator for basic and diluted earnings per common share: |
|
|
|
|
|
|
|
|
Weighted-average common shares outstanding - basic |
|
| 89,704 |
|
|
| 88,722 |
|
Effect of dilutive common shares |
|
| 2,227 |
|
|
| 2,033 |
|
Weighted average common shares outstanding-diluted |
|
| 91,931 |
|
|
| 90,755 |
|
Net income per common shares-basic |
| $ | 0.10 |
|
| $ | 0.21 |
|
Net income per common shares-diluted |
| $ | 0.09 |
|
| $ | 0.20 |
|
|
|
|
|
|
|
|
| |
Adjusted earnings per share |
|
|
|
|
|
|
|
|
Net income |
| $ | 8,656 |
|
| $ | 18,546 |
|
Refinancing costs |
|
| - |
|
|
| 1,645 |
|
Gross adjustments to EBITDA |
|
| 4,528 |
|
|
| 9,333 |
|
Tax adjustment (1) |
|
| 235 |
|
|
| (880 | ) |
Adjusted net income |
| $ | 13,419 |
|
| $ | 28,644 |
|
Adjusted diluted earnings per share |
| $ | 0.15 |
|
| $ | 0.32 |
|
|
|
|
|
|
|
|
| |
Diluted earnings per share to adjusted earnings per share |
|
|
|
|
|
|
|
|
Net income per common shares-diluted |
| $ | 0.09 |
|
| $ | 0.20 |
|
Adjustments to diluted earnings per share: |
|
|
|
|
|
|
|
|
Refinancing costs |
|
| - |
|
|
| 0.02 |
|
Other income |
|
| (0.02 | ) |
|
| (0.05 | ) |
Transaction expenses |
|
| 0.02 |
|
|
| 0.03 |
|
Stock-based compensation |
|
| 0.04 |
|
|
| 0.08 |
|
Acquisition and facility integration costs |
|
| 0.02 |
|
|
| 0.05 |
|
Tax adjustment (1) |
|
| (0.00 | ) |
|
| (0.01 | ) |
Adjusted earnings per share |
| $ | 0.15 |
|
| $ | 0.32 |
|
The tax adjustment represents the tax effect of the adjustments at the applicable effective tax rate. To determine the applicable effective tax rate, refinancing costs, other income, transaction expenses, stock-based compensation, and acquisition and facility integration costs are excluded from adjusted net income and therefore we have excluded the impact those items have on the effective tax rate.___
SOURCE: Loar Group Inc.
View the original press release on accesswire.com
Loar Group Inc.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom